< Previous2031st ECCMID ONLINE – INDUSTRY GUIDE 2762 16:15 - 18:15 13. Integrated sessions - 1 2-hour Integrated Symposium Importance of influenza vaccination in the COVID-19 environment Chair Orly Vardeny (Minneapolis, United States) ESCMID-appointed chair Jean-Paul Stahl (Grenoble, France) 2762-1 16:15 Welcome and introduction 2762-2 16:20 The burden of disease of influenza and COVID-19 John Paget (Utrecht, Netherlands) 2762-3 16:35 Influenza as a trigger for cardiovascular events Orly Vardeny (Minneapolis, United States) 2762-4 16:55 Correlation does not equal causation. The value and risks of randomised vs observational evidence in vaccine studies Francesca Dominici (Boston, United States) 2762-5 17:15 Towards increased awareness on the evidence quality and data robustness for vaccines efficacy and effectiveness: STIKO’ GRADE analysis for newer influenza vaccines in Germany Joerg Schelling (Munich, Germany) 2762-6 17:35 Panel discussion and Q&A Organised by SanofiPasteur Friday, 9 July 20212131st ECCMID ONLINE – INDUSTRY GUIDE 2711 16:15 - 18:15 14. Integrated Sessions – 2 2-hour Integrated Symposium Superbugs, Susceptibility & Stewardship: with more antibiotics available for multidrug-resistant Gram-negative bacterial infections, what’s holding us back? Chair Souha S. Kanj (Beirut, Lebanon) ESCMID-appointed chair Lior Nesher (Be’er Sheva, Israel) 2711-1 16:15 Opening remarks by the Chairs 2711-2 16:20 Antimicrobial stewardship and multidrug-resistant Gram-negative bacteria Louise Sweeney (Manchester, United Kingdom) 2711-3 16:40 How rapid diagnostics are changing treatment approaches Stefania Stefani (Catania, Italy) 2711-4 17:00 Where does a new carbapenem/BLI fit in the armamentarium against multidrug-resistant Gram-negative bacteria? Matteo Bassetti (Genoa, Italy) 2711-5 17:20 How do we make the most of the new treatments to achieve the best patient outcomes? Ryan Shields (Pittsburgh, United States) 2711-6 17:40 Discussion and live Q&A 2711-7 18:10 Closing remarks by the Chairs Organised by Menarini Friday, 9 July 20212231st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 2694 16:15 - 18:15 15. Integrated Sessions – 3 2-hour Integrated Symposium Deciphering the data: clinical impact of vaccines and monoclonal antibodies for COVID-19 Chair Tobias Welte (Hannover, Germany) ESCMID-appointed chair Ashleigh Tuite (Toronto, Canada) 2694-1 16:15 Welcome and opening remarks by the Chairs 2694-2 16:20 Introduction Tobias Welte (Hannover, Germany) 2694-3 16:30 COVID-19 vaccines: current and future outlooks Kirsty Le Doare (London, United Kingdom) 2694-4 16:50 Q&A Kirsty Le Doare (London, United Kingdom), Ashleigh Tuite (Toronto, Canada), Tobias Welte (Hannover, Germany) 2694-5 17:00 Monoclonal antibody therapies for COVID-19: applications and implications Hugh Montgomery (London, United Kingdom) 2694-6 17:20 Q&A Hugh Montgomery (London, United Kingdom), Ashleigh Tuite (Toronto, Canada), Tobias Welte (Hannover, Germany) 2694-7 17:30 Life in the changing pandemic landscape Barbara Rath (Berlin, Germany) 2694-8 17:50 Q&A Barbara Rath (Berlin, Germany), Ashleigh Tuite (Toronto, Canada), Tobias Welte (Hannover, Germany) 2694-9 18:00 Wrap up and closing remarks by the Chairs Organised by AstraZeneca2331st ECCMID ONLINE – INDUSTRY GUIDE Friday, 9 July 2021 2696 16:15 - 17:45 16. Integrated Sessions – 4 1,5-hour Integrated Symposium The role of patients in infectious disease research: from study participants to scientific partners Chair Nikhil Wagle (Boston, United States) ESCMID-appointed chair Daniel Diekema (Iowa City, United States) 2696-1 16:15 Introduction and objectives 2696-2 16:22 Our commitment to patients and infectious disease Pol Vandenbroucke (New York, United States) 2696-3 16:25 An emerging science: making the case for patient-partnered research Nikhil Wagle (Boston, United States) 2696-4 16:35 Finding funding: how foundations can facilitate patient-partnered research Gemma Buckland Merrett (Brighton, United Kingdom) 2696-5 16:45 Patient-partnered publications: the journals’ perspective Amy Price (Palo Alto, United States) 2696-6 16:55 From concept to action: three case studies of patient participation in research (EKPF) Daniel Gallego (Torrent, Spain) 2696-7 17:05 From concept to action: three case studies of patient participation in research (IAPO) Neda Milevska Kostova (Skopje, North Macedonia, Republic of) 2696-8 17:15 From concept to action: three case studies of patient participation in research (Sepsis Alliance) Thomas Heymann (San Diego, United States) 2696-9 17:25 Discussion and Q&A 2696-10 17:40 Summary and closing remarks by the Chairs Organised by Pfizer2431st ECCMID ONLINE – INDUSTRY GUIDE Saturday, 10 July 2021 2695 08:30 - 09:30 13. Integrated sessions – 1 1-hour Integrated Symposium An innovative approach to infection control ESCMID-appointed chair Colin R. Mackenzie (Düsseldorf, Germany) 2695-1 08:30 Welcome and introduction 2695-2 08:35 CRE and VRE screening pre- and post-SARS-CoV-2 pandemic, an undervalued need Alberto Antonelli (Florence, Italy) 2695-3 09:00 The surveillance of VRE and CRE in long-stay patients at a Korean Nationwide Veterans Hospital Eunsin Bae (Seoul, Korea, Republic of) 2695-4 09:25 Panel discussion and Q&A Organised by Seegene Inc.2531st ECCMID ONLINE – INDUSTRY GUIDE Saturday, 10 July 2021 2763 08:30 - 10:00 14. Integrated Sessions – 2 1,5-hour Integrated Symposium Surviving invasive meningococcal disease (IMD): the long-term impact and future preventive perspectives Chair Jean-Paul Stahl (Grenoble, France) ESCMID-appointed chair Emma Cecilia Wall (London, United Kingdom) 2763-1 08:30 Live opening and welcome by the Chairs 2763-2 08:35 Video presentation and live panel discussion Jean-Paul Stahl (Grenoble, France) Elena Moya (Madrid, Spain) Cohen Robert (Creteil, France) Marco Safadi (Sao Paulo, Brazil) Julio A. Vazquez Moreno (Majadahonda, Spain) Emma Cecilia Wall (London, United Kingdom) 2763-3 09:05 IMD prevention in the COVID-19 era: lessons learned and future directions Julio A. Vazquez Moreno (Majadahonda, Spain) 2763-4 09:25 Advances in IMD prevention options Marco Safadi (Sao Paulo, Brazil) 2763-5 09:45 Discussion and Q&A Organised by SanofiPasteur2631st ECCMID ONLINE – INDUSTRY GUIDE Saturday, 10 July 2021 2697 08:30 - 10:30 15. Integrated Sessions – 3 2-hour Integrated Symposium Gram-negative infections in the post-COVID world: what are we left with? Chair Eleni Giamarellou (Athens, Greece) ESCMID-appointed chair Alasdair Macgowan (Bristol, United Kingdom) 2697-1 08:30 Welcome, introduction and opening remarks by the Chairs 2697-2 08:35 COVID-19: an antibiotic stewardship tug of war over antibiotic resistance? Matteo Bassetti (Genoa, Italy) 2697-3 08:50 The heterogeneity of pneumonia: one size may not fit all Ricard Ferrer Roca (Barcelona, Spain) 2697-4 09:10 From evidence to practice: guideline updates Souha S. Kanj (Beirut, Lebanon) 2697-5 09:30 Clinical trial updates: adding to the puzzle but looking for more pieces Andrew Shorr (Washington DC, United States) 2697-6 09:50 What’s flowing down the pipeline? David Paterson (Brisbane, Australia) 2697-7 10:05 Panel discussion and Q&A 2697-8 10:25 Closing remarks by the Chairs Organised by Merck Sharp & Dohme2731st ECCMID ONLINE – INDUSTRY GUIDE Saturday, 10 July 2021 2698 09:00 - 10:30 16. Integrated Sessions – 4 1,5-hour Integrated Symposium Novel rapid diagnostic solutions aiming to improve the diagnosis of C. difficile infections and respiratory infections ESCMID-appointed chair Harald Seifert (Cologne, Germany) 2698-1 09:00 Welcome and introduction Harald Seifert (Cologne, Germany) 2698-2 09:15 Prospective evaluation of combined antigen testing for C. difficile GDH and toxins Jürgen Becker (Kornwestheim, Germany) 2698-3 09:45 How innovative sample-in-result-out rapid molecular testing platforms can impact testing environments Frédéric Barbut (Paris, France) 2698-4 10:15 Discussion and Q&A Organised by Quidel Ireland Ltd.2831st ECCMID ONLINE – INDUSTRY GUIDE Saturday, 10 July 2021 2702 13:15 - 14:45 13. Integrated sessions - 1 1,5-hour Integrated Symposium Adult pneumococcal vaccination: evidence to inform optimal policy for at-risk groups and the role of polysaccharide vaccines Chair Rachel Dawson (Killeen-Temple-Fort Hood, United States) ESCMID-appointed chair Mario Ramirez (Lisbon, Portugal) 2702-1 13:15 Welcome, introduction and opening remarks by the Chairs 2702-2 13:20 Serotype epidemiology of pneumococcal disease in patients with chronic medical conditions Carmen Ardanuy Tisaire (L’Hospitalet De Llobregat, Spain) 2702-3 13:35 Pneumococcal disease risk stacking and its implications for adult vaccination policy Aisling Caffrey (Kingston, United States) 2702-4 13:55 Recent studies on the effectiveness of pneumococcal polysaccharide vaccines and future directions for pneumococcal disease prevention in adults Daniel Musher (Houston, United States) 2702-5 14:20 Discussion and Q&A 2702-6 14:40 Closing remarks by the Chairs Organised by Merck Sharp & Dohme2931st ECCMID ONLINE – INDUSTRY GUIDE Saturday, 10 July 2021 2700 13:15 - 15:15 14. Integrated Sessions – 2 2-hour Integrated Symposium Taking a look inside the Trojan horse Chair Robert Krause (Graz, Austria) ESCMID-appointed chair Emil P. Lesho (Rochester, United States) 2700-1 13:15 Welcome and introduction by the Chairs 2700-2 13:25 The evolving landscape of Gram-negative resistance Marco Falcone (Pisa, Italy) 2700-3 13:40 Cefiderocol: what’s different about a siderophore cephalosporin Stefania Stefani (Catania, Italy) 2700-4 14:00 APEKS & CREDIBLE-CR: lessons learnt from a Gram-negative focused clinical development programme Ricard Ferrer Roca (Barcelona, Spain) 2700-5 14:20 Q&A session with presenters 2700-6 14:30 Expert Panel: early clinical experience in the use of cefiderocol Sarah Tschudin Sutter (Basel, Switzerland), Aurélien Dinh (Garches, France), Marco Falcone (Pisa, Italy) 2700-7 15:00 Q&A session with panel experts and closing remarks Organised by Shionogi & Co., Ltd. Next >